108 BioCapital

108 BioCapital is a U.S.-based private equity firm focused on growth-stage investments in biotech and medtech companies developing scalable, exit-driven solutions that address high-impact unmet medical needs. We invest in businesses with clear and accelerated regulatory pathways, validated clinical or technical foundations, and a line of sight to meaningful commercial adoption. At 108 BioCapital, we are dedicated to advancing the frontiers of medical innovation. Our mission is to invest in transformative healthcare solutions that address urgent unmet medical needs, improve patient outcomes, and deliver sustained value to our investors. The US healthcare and medtech sectors present an extraordinary growth opportunity, with healthcare spending projected to reach 20% of GDP by 2032. Advances in diagnostics, therapeutic devices, and personalized medicine are reshaping the industry. We seek to partner with visionary entrepreneurs and management teams, leveraging our expertise and network to accelerate growth and maximize impact.